Clinical trials
Respiratory Syncytial Virus (RSV) clinical trials
Below are recruiting respiratory syncytial virus (rsv) clinical trials, each written for real people, not researchers. We’re tracking 38 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07358910Recruiting
Tracking infectious diseases in communities
This study looks at how infections spread in villages in Cambodia. If you live in a participating village, you might help us understand and prevent disease outbreaks.
Phnom Penh, Phnom PenhAges 2–75 - NCT07272434RecruitingPhase 3
RSV vaccine trial for adults 60 and older
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
Guangzhou, GuangdongAges 60 years+ - NCT07239583Recruiting
RSV infection and health impact in older adults in Vietnam
This study looks at how common RSV (a virus that can cause serious breathing problems) is in older adults who are hospitalized with respiratory symptoms or worsening heart/lung conditions. By joining, you help researchers understand the virus and improve care for people your age.
Ho Chi Minh City, Southern VietnamAges 60 years+ - NCT07214571RecruitingPhase 2
Study of S-337395 for RSV in high-risk adults
This trial tests an experimental drug called S-337395 for adults with RSV who are not in the hospital but are at high risk for severe illness. It aims to see if the drug can help prevent symptoms from getting worse.
Los Angeles, CaliforniaAges 18 years+ - NCT07158814RecruitingPhase 4
Testing the safety of an RSV antibody in infants
This study checks if it is safe to delay the RSV preventive antibody shot by up to two weeks in infants who are getting their routine vaccines. Your baby will get the antibody at a second visit.
Oakland, CaliforniaAges 1 month–7 months - NCT07516418RecruitingPhase 1
RSV and Flu H5 Vaccine Formulations Study
This study tests different versions of experimental vaccines designed to protect against RSV (a common respiratory virus) and flu H5. You'll receive one of these vaccines and be monitored to see how safe it is and how your body responds.
Griffith, QueenslandAges 18–49 - NCT07578298RecruitingPhase 4
RSV protection for aboriginal infants
This study tests an RSV antibody shot that helps protect babies from severe RSV. It aims to see how well this preventive shot works in Aboriginal and Torres Strait Islander infants when given around 6-9 months of age.
Darwin, Northern TerritoryAges 6 months–9 months - NCT07106918RecruitingEarly Phase 1
SIBP-A16 Injection Safety Study in Healthy Adults
This study tests an experimental injection called SIBP-A16 in healthy adults to see if it is safe and how the body handles it. It helps researchers learn about the drug before testing it in people with a medical condition.
WuhanAges 18–45 - NCT07050732RecruitingPhase 2
Testing RSV vaccine in people with weakened immune systems
This study tests an RSV vaccine in people with weakened immune systems (like transplant recipients) and in older adults. It aims to see how well the vaccine boosts protection against RSV, a common respiratory virus.
Baltimore, MarylandAges 18 years+ - NCT06998251Recruiting
Immune response to strep pneumonia in older adults
This study looks at how the immune system in the nose and throat reacts to Streptococcus pneumoniae bacteria and viruses in adults aged 60-85. It may help researchers find better ways to prevent or treat pneumonia.
GenevaAges 60–85 - NCT07582796RecruitingPhase 1/Phase 2
RSV Vaccine Study for Adults in China
This study tests a new vaccine to protect against RSV (a common respiratory virus that causes cold-like illness, especially serious in older adults). The vaccine is made in laboratory cell cultures and includes an immune-boosting ingredient. Researchers want to see if it's safe and if it helps your body fight RSV infection.
Zigong, SichuanAges 18 years+ - NCT06881953Recruiting
Preventing RSV in infants in France
This trial studies ways to prevent RSV infections in newborns. If you are a parent who gave birth in France between October 2024 and January 2025, you may be able to help researchers learn how to better protect babies from RSV.
ParisAges 18 years+ - NCT06881056Recruiting
Aerosol interferon for RSV pneumonia in toddlers
This study tests an inhaled form of peginterferon alpha-2b for children aged 1 to 3 years who have pneumonia caused by RSV. The goal is to see if this treatment helps them recover faster.
Chengdu, SichuanAges 1–3 - NCT06873633RecruitingPhase 2
Testing remdesivir for RSV in hospitalized children under 2
This trial tests if remdesivir (Veklury) is safe and helps clear RSV in babies and toddlers who are hospitalized. It may help your child recover faster from severe RSV symptoms.
BangkokAges birth–2 years - NCT06754605RecruitingPhase 1/Phase 2
Testing a new RSV vaccine for safety and immune response
This trial tests a new RSV vaccine in two phases. First, it will be given to healthy adults 18 and older to check safety. Then, it will be studied in adults 50 and older, including those with stable health conditions, to see if it helps protect against RSV, a common virus that can cause serious breathing problems in older people.
Langfang, HebeiAges 18–120 - NCT06684379RecruitingPhase 1/Phase 2
Two Doses of PRS CK STORM for Severe Viral Pneumonia
This study tests a new drug called PRS CK STORM to see if it can safely calm the body's overactive immune response (cytokine storm) in people with severe pneumonia from COVID-19, flu, or RSV who need oxygen. It aims to reduce inflammation and improve recovery.
Alcalá de Henares, MadridAges 18 years+ - NCT06665100RecruitingPhase 2
Study of PUL-042 for RSV and Related Viruses in Immune-Compromised Patients
This trial tests an inhaled medicine (PUL-042) for people with blood cancers or who have had a stem cell transplant and now have a respiratory virus (parainfluenza, RSV, or human metapneumovirus). The goal is to see if the drug can help clear the virus and improve symptoms.
Duarte, CaliforniaAges 18 years+ - NCT06521944Recruiting
RSV vaccine safety registry for pregnant people
This registry follows pregnant people who received an RSV vaccine during a specific window (32 to 36 weeks) to monitor safety. If you got the shot in that time, your information helps researchers understand how well the vaccine works in pregnancy.
Wilmington, North CarolinaAges 18–50 - NCT06488300RecruitingPhase 2
Testing antiviral treatments for early RSV
This trial tests if antiviral medications can help adults with early respiratory syncytial virus (RSV) feel better faster. It is for people aged 18 to 64 who have had RSV symptoms for 4 days or less and have tested positive for the virus.
VientianeAges 18–64 - NCT06363370RecruitingPhase 3
Interferon inhalation for RSV in children under 2
This trial tests if an inhaled interferon solution can help children under 2 years old with a moderate to severe RSV lung infection. It aims to reduce symptoms like cough and trouble breathing.
Beijing, Beijing MunicipalityAges 2 months–2 years - NCT07658534RecruitingPhase 2/Phase 3
Ziresovir for high-risk adults with RSV
This trial tests an antiviral drug called Ziresovir in adults with RSV who have health conditions that make them high-risk, such as lung disease, heart disease, or a weakened immune system. It aims to see if the drug can reduce symptoms like coughing and shortness of breath.
Beijing, Beijing MunicipalityAges 18–85 - NCT06197152Recruiting
RSV severity markers in hospitalized adults
This study looks for markers in the blood that can tell how serious an RSV infection might become. If you are hospitalized with RSV and have breathing symptoms, this trial will follow your recovery and test for clues about your illness.
CréteilAges 18 years+ - NCT05655182RecruitingPhase 1/Phase 2
RSV vaccine study for infants and toddlers who may be at risk
This Phase 1/2 study tests an RSV vaccine (BLB-201) in infants and young children. It aims to see how the vaccine works and how safe it is, including in children who already have RSV antibodies or not.
La Mesa, CaliforniaAges 6 months–5 years - NCT07482657RecruitingPhase 2
Zelicapavir for RSV in infants and toddlers
This trial tests a new medicine called Zelicapavir for babies and young children (28 days to 3 years old) who have respiratory syncytial virus (RSV) infection. The medicine aims to help them recover faster and with fewer complications.
BangkokAges 4 weeks–3 years
Hear when a new Respiratory Syncytial Virus (RSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for respiratory syncytial virus (rsv)?
- Yes. Clin2 currently lists 38 recruiting respiratory syncytial virus (rsv) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a respiratory syncytial virus (rsv) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a respiratory syncytial virus (rsv) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.